Silence Therapeutics begins dosing in lipoprotein treatment trial
Silence Therapeutics
535.00p
16:34 29/11/21
Silence Therapeutics has started dosing subjects in the ‘APOLLO’ phase 1 clinical study of its wholly-owned lead product candidate ‘SLN360’, it announced on Wednesday, for the treatment of elevated lipoprotein-a (Lp(a)) levels.
FTSE AIM 100
3,628.91
16:49 25/04/24
FTSE AIM 50
3,950.61
16:49 25/04/24
FTSE AIM All-Share
753.12
16:50 25/04/24
Pharmaceuticals & Biotechnology
22,750.48
17:09 25/04/24
The AIM-traded firm said the first-in-human study was investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels of at least 60 milligrams per decilitre.
“The APOLLO trial is a global, randomized, double-blind, placebo controlled, single-ascending and multiple-ascending dose study enrolling approximately 88 subjects total in up to nine cohorts,” the Silence board explained in its statement.
The company said it intended to report data from the single-ascending dose portion of the study in the second half of the year.
At 1044 GMT, shares in Silence Therapeutics were down 1.32% at 600p.